Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 382 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IIIA Non-small Cell Lung Cancer Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

NCT00444223
View directory record Official record
Conditions
Lung Cancer
Interventions
fluorine F 18 FEQA + positron emission tomography
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 2, 2026, 5:16 AM EDT
Withdrawn Phase 2 Interventional

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT02607423
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Computed Tomography, Docetaxel, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Pemetrexed Disodium, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00020709
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, docetaxel, etoposide, gefitinib, radiation therapy, placebo
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 2, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

NCT02987998
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Pembrolizumab, Radiation
Drug
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 2, 2026, 5:16 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

NCT02503722
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 2, 2026, 5:16 AM EDT
Terminated Early Phase 1 Interventional Results available

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

NCT03870529
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7, Stage IIA Lung Carcinoma, Stage IIIA Lung Carcinoma
Interventions
Vitamin A Compound, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

NCT00003869
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboxyamidotriazole, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 2, 2026, 5:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00078390
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
Interventions
S-3304, Chemo-irradiation
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
La Jolla, California • Washington D.C., District of Columbia • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00227539
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, pemetrexed disodium, adjuvant therapy, therapeutic conventional surgery, fludeoxyglucose F 18
Drug · Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 2, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional Results available

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

NCT03455556
View directory record Official record
Conditions
Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 2, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

NCT00049608
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
mistletoe extract, gemcitabine hydrochloride
Dietary Supplement · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

NCT00002930
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer
Interventions
positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

NCT02897375
View directory record Official record
Conditions
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
Interventions
Carboplatin, Cisplatin, Palbociclib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT00003901
View directory record Official record
Conditions
Lung Cancer
Interventions
immunohistochemistry staining method, biopsy, surgery
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
56
States / cities
Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00280150
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00182806
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 2, 2026, 5:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00547443
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, sorafenib tosylate, radiation therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

NCT00033384
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
CI-1040
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 2, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00563784
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 2, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT01935947
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Docetaxel, Entinostat, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 2, 2026, 5:16 AM EDT